Cowen analyst Marc Frahm reiterated an Outperform rating on Blueprint Medicines (NASDAQ: BPMC) after concerns over avapritinib's safety profile have ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE